This website uses cookies to improve your experience, read more about our use of cookies in the cookies and tracking policy

Who We Are

At Qbtech, we are passionate about transforming healthcare and empowering healthcare professionals, clinics and patients in their decision-making by providing a better view of ADHD.

The Qbtech Story

The story of Qbtech (Quantitative behaviour technology) began in Gothenburg, Sweden in 2002. By developing proprietary algorithms, a unique Continuous Performance Task (CPT) and adding important activity measures, Qbtech created an objective test, QbTest, with the ability to aid in the assessment of ADHD and treatment follow-up in both clinical and research settings.

In 2005, 2012 and 2014, three major milestones occurred as QbTest received FDA clearances for diagnostic assessment and treatment follow-up, further validating Qbtech’s commitment to quality.

Since 2009, Qbtech has grown significantly and our presence has expanded worldwide with local offices in the UK, Germany and the United States. So far, more than 300,000 patients have been evaluated using QbTest. As we continue to grow and get to know our customers better, we at Qbtech are proud to continue developing products that can empower well-informed decision-making.

What We Do

As a market leader in objective ADHD treatment follow up and diagnostic assessments, we are continuously working to design and develop a more effective tool to assist in the diagnosis and monitoring of ADHD. We work closely with several ADHD research groups who specialize in either children or adults, conducting studies to:

  • Better discriminate ADHD from other conditions with similar symptoms

  • Evaluate and understand the effects of pharmacological and non-pharmacological treatments

  • Test the utility of our QbTest

Our Management Team

Carl Reuterskiöld


Carl joined Qbtech in 2009. His previous experience includes various commercial and leadership roles within Pfizer as well as strategic and analytical roles within the Boston Consulting Group. M.Sc.

Hans Boström

Medical Director

Hans has a M.Sc. in Pharmacy and PhD in Biochemistry. He joined Qbtech in 2010 and has an extensive experience within Clinical Research and Regulatory Affairs from different positions in the Life Science industry.

Tony Doyle

Commercial Director

Before joining Qbtech in 2010, Tony worked at Pfizer where he gained extensive experience leading strategic and commercial groups in the UK and across Europe. B.Sc.

Gunnar Haawind


Gunnar holds a M.Sc. in Business Administration and Economics. He joined Qbtech in 2012 and has worked as a consultant at PwC with a portfolio of international clients from mainly Pharma and the Retail industry.